Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 USD | +1.19% | +10.61% | -2.14% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 117.4 and 65.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.14% | 1.83B | C- | ||
+26.47% | 664B | C+ | ||
+26.74% | 567B | B | ||
-6.33% | 354B | C+ | ||
+19.35% | 330B | B- | ||
+4.23% | 286B | C+ | ||
+13.43% | 234B | B+ | ||
+4.71% | 199B | B- | ||
-9.53% | 196B | A+ | ||
-4.04% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMRX Stock
- Ratings Amneal Pharmaceuticals, Inc.